A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515617-18-00

Acronym

XL092-001

Enrollment

140

Registered

2024-09-11

Start date

2022-02-14

Completion date

Unknown

Last updated

2025-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced clear cell renal cell carcinoma (ccRCC), colorectal cancer (CRC), hormone receptor-positive breast cancer (HR+ BC), metastatic castration-resistant prostate cancer (mCRPC), non-clear cell renal cell carcinoma (nccRCC)

Interventions

None listed

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Countries

Belgium, Czechia, France, Germany, Spain

Outcome results